A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone.

Trial Profile

A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Zoledronic acid (Primary) ; Antiandrogens
  • Indications Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.
    • 16 Feb 2013 Primary endpoint 'Time-to-first-skeletal-event' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top